PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Market outline PART 05: Peptic ulcers: Disease overview PART 06: Key clinical trials PART 07: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 08: Market segmentation by drug class • PPIs • Antibiotics • Others PART 09: Geographical segmentation • Peptic ulcer drugs market in Americas • Peptic ulcer drugs market in EMEA • Peptic ulcer drugs market in APAC PART 10: Decision framework PART 11: Drivers and challenges • Market drivers • Market challenges PART 12: Market trends • Bismuth-based quadruple therapy • Emergence of monotherapy • Recurrent H. pylori infections • Rise in awareness PART 13: Vendor landscape • Competitive scenario PART 14: Key vendor analysis • AstraZeneca • Daewoong Pharmaceuticals • Eisai • Takeda Pharmaceutical • Other prominent vendors PART 15: Appendix • List of abbreviations List of Exhibits Exhibit 01: Types of peptic ulcer Exhibit 02: Global peptic ulcer drugs market: Pipeline landscape based on sponsors Exhibit 03: Global peptic ulcer drugs market: Pipeline landscape Exhibit 04: Global peptic ulcer drugs market: List of clinical trials and their aim/purpose Exhibit 05: Snapshot of global peptic ulcer drugs market Exhibit 06: Global peptic ulcer drugs market 2016-2021 ($ millions) Exhibit 07: Opportunity analysis in global peptic ulcer drugs market Exhibit 08: Five forces analysis Exhibit 09: Segmentation of global peptic ulcer drugs market based on drug class 2016 Exhibit 10: Global peptic ulcer drugs market share based on drug class 2016 Exhibit 11: Global peptic ulcer PPIs drugs market 2016-2021 ($ millions) Exhibit 12: Global peptic ulcer antibiotics drugs market 2016-2021 ($ millions) Exhibit 13: Global peptic ulcer drugs market for others 2016-2021 ($ millions) Exhibit 14: Segmentation of global peptic ulcer drugs market based on geography 2016 and 2021 Exhibit 15: Segmentation of global peptic ulcer drugs market revenue based on geography 2016-2021 Exhibit 16: Segmentation of global peptic ulcer drugs market based on geography 2016-2021 (%) Exhibit 17: Market scenario in Americas Exhibit 18: Peptic ulcer drugs market in Americas 2016-2021 ($ millions) Exhibit 19: Market scenario in EMEA Exhibit 20: Peptic ulcer drugs market in EMEA 2016-2021 ($ millions) Exhibit 21: Market scenario in APAC Exhibit 22: Peptic ulcer drugs market in APAC 2016-2021 ($ millions) Exhibit 23: Age-related proportion of patients with duodenal and gastric ulcer Exhibit 24: Some of the marketed combination products Exhibit 25: Revenue erosion of Pariet after loss of exclusivity Exhibit 26: Competitive structure analysis of global peptic ulcer drugs market 2016 Exhibit 27: AstraZeneca: Key highlights Exhibit 28: AstraZeneca: Strength assessment Exhibit 29: AstraZeneca: Strategy assessment Exhibit 30: AstraZeneca: Opportunity assessment Exhibit 31: Daewoong Pharmaceuticals: Key highlights Exhibit 32: Daewoong Pharmaceuticals: Strength assessment Exhibit 33: Daewoong Pharmaceuticals: Strategy assessment Exhibit 34: Daewoong Pharmaceuticals: Opportunity assessment Exhibit 35: Eisai: Key highlights Exhibit 36: Eisai: Strength assessment Exhibit 37: Eisai: Strategy assessment Exhibit 38: Eisai: Opportunity assessment Exhibit 39: Takeda Pharmaceutical: Key highlights Exhibit 40: Takeda Pharmaceutical: Strength assessment Exhibit 41: Takeda Pharmaceutical: Strategy assessment Exhibit 42: Takeda Pharmaceutical: Opportunity assessment

AstraZeneca, Daewoong Pharmaceuticals, Eisai, and Takeda Pharmaceutical.GlaxoSmithKline and Pfizer.